Shigeharu Uchiyama

Shigeharu Uchiyama

Auto-generated profile, based on publicly available information

Shigeharu Uchiyama

Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The Journal of Hand Surgery
Verified
Journal Article
Closed access
YTYasushi Terayama
Yasushi Terayama
SUShigeharu Uchiyama
Shigeharu Uchiyama
KUKazuhiko Ueda
Kazuhiko Ueda
NINahoko Iwakura
Nahoko Iwakura
SIShota Ikegami
Shota Ikegami
HKHiroyuki Kato
Hiroyuki Kato

1 November 2013 in The Bone & Joint Journal
Verified
Journal Article
Closed access
SUS. Uchiyama
S. Uchiyama
TIT. Itsubo
T. Itsubo
KNK. Nakamura
K. Nakamura
YFY. Fujinaga
Y. Fujinaga
NSN. Sato
N. Sato
HKH. Kato
H. Kato
This multicentre prospective clinical trial aimed to determine whether early administration of alendronate (ALN) delays fracture healing after surgical treatment of fractures of the distal radius. The study population comprised 80 patients (four men and 76 women) with a mean age of 70 years (52 to 86) with acute fragility fractures of the distal radius requiring open reduction and internal fixation with a volar locking plate and screws. Two groups of 40 patients each were randomly allocated either to receive once weekly oral ALN administration (35 mg) within a few days after surgery and continued for six months, or oral ALN administration delayed until four months after surgery. Postero-anterior and lateral radiographs of the affected wrist were taken monthly for six months after surgery. No differences between groups was observed with regard to gender (p = 1.0), age (p = 0.916), fracture classification (p = 0.274) or bone mineral density measured at the spine (p = 0.714). The radiographs were assessed by three independent assessors. There were no significant differences in the mean time to complete cortical bridging observed between the ALN group (3.5 months (se 0.16)) and the no-ALN group (3.1 months (se 0.15)) (p = 0.068). All the fractures healed in the both groups by the last follow-up. Improvement of the Quick-Disabilities of the Arm, Shoulder and Hand (QuickDASH) score, grip strength, wrist range of movement, and tenderness over the fracture site did not differ between the groups over the six-month period. Based on our results, early administration of ALN after surgery for distal radius fracture did not appear to delay fracture healing times either radiologically or clinically. Cite this article: Bone Joint J 2013;95-B:1544–50.

15 December 2015 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
YNYukio Nakamura
Yukio Nakamura
MKMikio Kamimura
Mikio Kamimura
SIShota Ikegami
Shota Ikegami
KMKeijiro Mukaiyama
Keijiro Mukaiyama
SUShigeharu Uchiyama
Shigeharu Uchiyama
HKHiroyuki Kato
Hiroyuki Kato
Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-β ligand (RANKL). Previous reports have shown that denosumab treatment of osteoporotic patients decreases bone resorption and fracture risk, but there have been no clinical studies on changes in bone turnover markers, 1,25(OH)2D3, or parathyroid hormone (PTH) in denosumab therapy with or without bisphosphonate (BP) pre-treatment in Japan. Here, we report such findings in 22 patients (11 in the denosumab alone group and 11 in the BP pre-treated group) with osteoporosis following 4 months of treatment. Bone metabolism had been inhibited by prior BP administration in the BP pre-treated group. The bone resorption markers serum tartrate-resistant acid phosphatase type 5b and urinary type I collagen cross-linked N-telopeptide were significantly decreased from baseline values for the entire study period in both groups. The bone formation marker bone alkaline phosphatase was significantly decreased at 4 months in the denosumab alone group only, and N-terminal propeptide of type 1 procollagen was significantly decreased at 2 and 4 months in the denosumab alone group versus no remarkable change in the BP pre-treated group. In the denosumab alone group, 1,25(OH)2D3 and PTH were significantly increased at 1 week and decreased gradually thereafter, but these did not change notably in the BP pre-treated group. Our results suggest that treatment with denosumab causes a strong inhibitory effect on bone resorption markers and mild inhibitory effect on bone formation markers. 1,25(OH)2D3 and PTH were significantly increased by denosumab but these did not change in the BP pre-treated group. Current Controlled Trials NCT02156960 . Registered 31 May 2014.

2 April 2022 in Nanomaterials
Verified
Journal Article
Open access
PDF file
MTManabu Tanaka
Manabu Tanaka
MIMakoto Izumiya
Makoto Izumiya
Hisao HaniuHisao Haniu
Hisao Haniu
KUKatsuya Ueda
Katsuya Ueda
CMChuang Ma
Chuang Ma
NSNaoto Saito
Naoto Saito
Nanomaterials show great promise as bone regeneration materials. They can be used as fillers to strengthen bone regeneration scaffolds, or employed in their natural form as carriers for drug delivery systems. A variety of experiments have been conducted to evaluate the osteogenic potential of bone regeneration materials. In vivo, such materials are commonly tested in animal bone defect models to assess their bone regeneration potential. From an ethical standpoint, however, animal experiments should be minimized. A standardized in vitro strategy for this purpose is desirable, but at present, the results of studies conducted under a wide variety of conditions have all been evaluated equally. This review will first briefly introduce several bone regeneration reports on nanomaterials and the nanosize-derived caveats of evaluations in such studies. Then, experimental techniques (in vivo and in vitro), types of cells, culture media, fetal bovine serum, and additives will be described, with specific examples of the risks of various culture conditions leading to erroneous conclusions in biomaterial analysis. We hope that this review will create a better understanding of the evaluation of biomaterials, including nanomaterials for bone regeneration, and lead to the development of versatile assessment methods that can be widely used in biomaterial development.

1 June 2015 in Bone
Verified
Journal Article
Closed access
SUShigeharu Uchiyama
Shigeharu Uchiyama
SIShota Ikegami
Shota Ikegami
MKMikio Kamimura
Mikio Kamimura
KMKeijiro Mukaiyama
Keijiro Mukaiyama
YNYukio Nakamura
Yukio Nakamura
HKHiroyuki Kato
Hiroyuki Kato

1 August 2008 in Journal of Hand Surgery (European Volume)
Verified
Journal Article
Closed access
HYH. Yamazaki
H. Yamazaki
SUS. Uchiyama
S. Uchiyama
YHY. Hata
Y. Hata
NMN. Murakami
N. Murakami
HKH. Kato
H. Kato
Non-rheumatoid osteoarthritis of the distal radioulnar joint can cause extensor tendon rupture. We analysed the radiographic morphology of the distal radioulnar joint to identify the risk factors for this complication. Forty-one wrist X-rays of 37 patients with extensor tendon rupture caused by distal radioulnar joint osteoarthritis were evaluated retrospectively for the severity of osteoarthritis by the Kellgren/Lawrence scoring system. Measurements were obtained from posteroanterior views. All but one wrist had severe osteoarthritic changes exceeding grade 3. The radiographic features that were different from those of the contralateral wrists included deepening and widening of the sigmoid notch, radial shift of the ulnar head and dorsal inclination of the sigmoid notch. There was no significant association between tendon rupture and the morphology of the ulnar head or ulnar variance. The scallop sign, dorsal inclination of the sigmoid notch and radial shift of the ulnar head are radiological risk factors for extensor tendon ruptures.